Search

137 Result(s)
Sort by

NeO - smart and sustainable vaccines

NeO - smart and sustainable vaccines

The reduction in the environmental impact of the new NeO vaccine packaging illustrates Boehringer Ingelheim’s drive for environmental responsibility.
COVID-19 IMI2–Call 21

COVID-19 IMI2–Call 21

CARE launched to accelerate therapy development against COVID-19 and future coronavirus threats.
Our Commitment

Our Commitment

We want to create value in areas of unmet medical need and engage with communities and society to improve lives – for humans and animals.
Making more health through animal health

Making more health through animal health

Boehringer Ingelheim and Ashoka aim to build a world with a greater access to health for people, animals and their communities.
Landmark EMPA-KIDNEY trial showed significant benefit of empagliflozin in reducing kidney disease progression or cardiovascular death by 28% vs. placebo in people with chronic kidney disease

Landmark EMPA-KIDNEY trial showed significant benefit of empagliflozin in reducing kidney disease progression or cardiovascular death by 28% vs. placebo in people with chronic kidney disease

EMPA-KIDNEY Phase III clinical trial met its primary endpoint by demonstrating a significant kidney and cardiovascular benefit for adults living with chronic kidney disease
International Women's Day

International Women's Day

We celebrate International Women’s Day with this year’s UN Women motto being “Gender Equality Today for a Sustainable Tomorrow”
Improving Access to Healthcare

Improving Access to Healthcare

According to the UN Sustainable Development Goals, almost half of the global population is not covered by essential health services.